IP Library › Granted Patent US 8,471,000
Granted Patent B2
US 8,471,000 · App. 13/474,405 · Granted Jun 25, 2013

RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,471,000
App. No.
13/474,405
Granted
Jun 25, 2013
Kind
B2
Abstract

RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

Claims (1)

1. A composition comprising an interfering RNA having a sense and an antisense strand, wherein each strand is 19-49 nucleotides in length, wherein the sense strand comprises the RNA sequence of SEQ ID NO: 3, and a pharmaceutically acceptable carrier, and wherein the interfering RNA is an siRNA that inhibits HIF1A.

Assignments (3)
CHANGE OF NAME Recorded Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068551/0357 →
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ALCON RESEARCH, LTD.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 035653/0635 →